Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial | Synapse
February 2, 2026Open Access
Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial
Key Points
Assess the efficacy and tolerability of ivarmacitinib in treating moderate to severe atopic dermatitis based on baseline patient characteristics.
Post-hoc analysis of a phase 3 clinical trial
Evaluated patient characteristics stratification
Measured efficacy and tolerability outcomes
Ivarmacitinib demonstrated notable efficacy in moderate to severe atopic dermatitis
Good tolerability observed across diverse patient characteristics
Abstract
Ivarmacitinib demonstrated efficacy and good tolerability in treating moderate to severe AD with diverse patient characteristics.